Search clinical trials for: OSPRO-ROS Questionnaire
Total 0 results
Nothing found
Sponsors and Collaborators
- Shanghai Huihe Medical Technology Co., Ltd
- The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Incept Biosystems
- Hirofumi Tanaka
- Dr. med. Sonja Diez
- PD Dr. med. MSc Giovanna Lurati Buse
- Canadian Research & Education in Arthritis
- University of Modena and Reggio Emilia, Modena, Italy
- NEOCOSUR
- Genome Identification Diagnostics GmbH
- Second People's Hospital of Yunnan Province
- Laboratoire Information Avignon université
- AIMST University
- Hellenic Cooperative Oncology Group
- Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital
- Vienna Dialysis Center
- OSMOS Clinical Research, Inc
- Nativis, Inc.
- Liliana Sollazzi
- genae associates (CRO), Antwerp, Belgium
- View Full List
Medical Conditions
- Breast Cancer With Metastatic Bone Disease
- BCLC Stage C Hepatocellular Carcinoma
- Alzheimer's Disease and Related Disorders (ADRD)
- Teledermatology
- Lipoid Urologic Disease
- Radiotherapy Induced Mucositis
- Congenital Scoliosis
- Facial Dryness
- Patient With Low Denisty Bone
- Endometrial Cancer Stage III
- Colic of Gallbladder Without Mention of Cholecystitis
- Superior Cluneal Nerve Entrapment Syndrome
- 3 Vessel Coronary Artery Disease
- Eosinophilic Duodenitis (EoD)
- Promoting Cardiovascular Health in Adults
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Adolescent Idiopathic Scoliosis, Lumbar Region
- Anemia, Refractory, with Excess of Blasts
- Manganese Safety in Pediatric Patients
- Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission
- View Full List
Drug Interventions
- RF-PSA
- Omeprazole, Lansoprazole, Esomeprazole, Rantidine
- Clindamycin
- Asparaginase
- RmhTNF-NC
- Test Drug
- Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
- Clarithromycin 500mg
- VNZ/TEZ/D-IVA
- PM8002
- Tacrolimus
- Pertuzumab
- Bevacizumab
- Gantenerumab
- Latanoprost 0.005% (drug)
- FOLFIRI Protocol
- CVL-231
- US-licensed Actemra
- Transversalis Fascia Plane Block
- Rebaudioside A
- View Full List
CROs by country
- Contract Research Organizations in Algeria
- Contract Research Organizations in Bahamas
- Contract Research Organizations in Congo
- Contract Research Organizations in Costa Rica
- Contract Research Organizations in Estonia
- Contract Research Organizations in Kenya
- Contract Research Organizations in Kuwait
- Contract Research Organizations in Montenegro
- Contract Research Organizations in New Zealand
- Contract Research Organizations in Serbia
- Contract Research Organizations in Slovenia
- Contract Research Organizations in Spain
- Contract Research Organizations in Uganda
- CRO list by country